Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Humabody Based Radiopharmaceutical
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Oranomed
Deal Size : Undisclosed
Deal Type : Collaboration
Orano Med Enters Pre-Clinical Collaboration With Crescendo Biologics
Details : The collaboration focuses on exemplify the benefit of Orano Med’s Targeted Alpha Therapies, using Humabody VH for precise targeting.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 07, 2024
Lead Product(s) : Humabody Based Radiopharmaceutical
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Oranomed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : CB307 is a CD137/PSMA dual inhibitor protein drug candidate administered via intravenous infusion for PSMA positive metastatic castration-resistant prostate cancer.
Brand Name : CB307
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 06, 2023
Lead Product(s) : CB307,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Sofinnova Partners
Deal Size : $32.0 million
Deal Type : Financing
Details : The proceeds will fund development of Crescendo's ongoing Phase 1b clinical trial of CB307 (tri-specific humabody) through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort in individuals with PSMA+ metastatic castration-resist...
Brand Name : CB307
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 24, 2023
Lead Product(s) : CB307,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Sofinnova Partners
Deal Size : $32.0 million
Deal Type : Financing
Angle PLC, Crescendo Biologics Ink Clinical Services Contract
Details : Under the agreement, Crescendo will use ANGLE's recently launched Portrait Flex assay in its Phase 1 trial investigating the safety and efficacy of CB307, a first-in-class PSMA x CD137 half-life extended bispecific, for treating patients with PSMA positi...
Brand Name : CB307
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 13, 2023
Details : Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against cancer a...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $40.0 million
January 10, 2022
Lead Product(s) : Humabody
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Crescendo Biologics Expands its Ongoing Collaboration with Takeda
Details : The expansion will enable Takeda to access a range of Crescendo’s half-life extension Humabodies for use with its two Humabody programmes, licensed in November 2018 and July 2019.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 10, 2020
Lead Product(s) : Humabody
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
LOOKING FOR A SUPPLIER?
Reset All
